From Almost Quitting to Full Adherence: GLP-1 Nausea Solved in 10 Weeks

A 55-year-old founder in New York had been on tirzepatide for six weeks and was already drafting the "I'm done" text to his prescriber. Nausea after every injection, reflux, one episode of vomiting, and an appetite so suppressed he was accidentally hitting 900 kcal on a working day. He is not unusual. Real-world adherence data on GLP-1s shows 15–25% discontinue in the first quarter, primarily for gastrointestinal side effects (Gleason et al., Obesity 2024). A titration and meal-sequence protocol kept him on the drug, on the plan, and off the quit list.

The presenting state

Full 5 mg tirzepatide dose. Injection Sunday night. Monday and Tuesday unusable. Reflux by Wednesday. Wednesday–Saturday functional but under-eating. Weight was dropping — largely from the fact that he was skipping meals in fear, not from the drug's satiety curve working properly. This is the classic path to a rebound and a rage-quit.

The protocol

Two changes to the medical plan (coordinated with his prescriber, not overruled) and four changes to how food and the injection intersected.

• Dose titration — coordinated with his prescriber: stepped back to 2.5 mg for four weeks, then re-ramped to 5 mg. The FDA titration schedule exists for a reason; jumping tiers is the single most common cause of avoidable nausea.
• Injection timing moved to Friday evening — the worst 48 hours landed on Saturday–Sunday, not Monday's board calls.
• Meal sequence rule — protein first, fibre second, starch last. Slower gastric emptying rewards this order and punishes the reverse (Shukla et al., BMJ Open Diabetes 2017).
• Smaller, more frequent meals — 5 × 400 kcal, not 3 × 700 kcal. Stopped the "full stomach on a slowed valve" reflux trigger.
• Hydration floor 2.8 L/day — GLP-1 dehydration is a silent nausea multiplier.
• No alcohol on injection day + 48h — halved the reflux events on its own.
• Ginger 500 mg with breakfast on injection day + 1 (Marx et al., Nutrients 2017).
• Journal (GLP-1 protocol) — nausea 0–10, reflux events, kcal, protein g, injection day. Adherence and side-effect trend visible in a single glance for both him and his prescriber.

What changed

• Nausea average post-injection: 7/10 → 2/10 by week 6.
• Vomiting episodes: 1 → 0 across the whole 10 weeks.
• Reflux events: 5/week → 1/week.
• Average intake: 900 kcal → 1,650 kcal — appropriate deficit, not accidental starvation.
• Weight: −8.4 kg across 10 weeks, holding lean mass by DEXA.
• Adherence: 100% of scheduled doses — vs the projected zero on his original trajectory.

Why this worked

Most GLP-1 discontinuations aren't a drug failure — they're a protocol failure around the drug. Titration, injection timing, meal sequence, hydration and alcohol account for the majority of avoidable side-effect load. When the Journal made the pattern visible to both patient and prescriber, dose decisions stopped being blind. He stayed on the medication. The medication stayed useful.

The founder-to-prescriber text he almost sent got replaced with a shared dashboard. That's the whole intervention.

Sources

• Gleason et al., 2024 — Real-world GLP-1 discontinuation, Obesity.
• Shukla et al., 2017 — Food order and glycemic response, BMJ Open Diabetes.
• Marx et al., 2017 — Ginger for nausea, Nutrients.
• FDA tirzepatide label — Titration schedule and side-effect profile.